Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The clinical study titled A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) aims to assess the safety and effectiveness of AMG 193, a MTA-cooperative PRMT5 inhibitor. This study focuses on patients with advanced thoracic tumors characterized by MTAP deletion, a genetic alteration. The study’s significance lies in its potential to offer new treatment options for these patients.
The study tests AMG 193, administered orally, both alone and in combination with other drugs like carboplatin, paclitaxel, pembrolizumab, pemetrexed, and sotorasib. These combinations target different subtypes of non-small cell lung cancer (NSCLC), including those with KRasG12C mutations and brain metastases.
The study is interventional, non-randomized, and follows a parallel assignment model without masking. Its primary purpose is treatment-focused, aiming to determine the maximum tolerated dose and recommended combination dose of AMG 193.
The study began on September 17, 2024, with its primary completion and estimated overall completion dates yet to be announced. The latest update was submitted on August 20, 2025, indicating ongoing recruitment and progress.
This study update from Amgen could influence the company’s stock performance positively, as successful outcomes may enhance its oncology portfolio. Investors should monitor developments closely, especially in the context of competing therapies targeting similar genetic mutations.
The study is currently ongoing, with further details available on the ClinicalTrials portal.